Exicure, Inc. (NASDAQ:XCUR) Sees Significant Decline in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 34,300 shares, a decrease of 23.3% from the March 15th total of 44,700 shares. Currently, 1.4% of the company’s shares are sold short. Based on an average daily volume of 62,000 shares, the days-to-cover ratio is presently 0.6 days.

Exicure Stock Performance

Shares of Exicure stock opened at $8.44 on Monday. The company’s 50 day moving average price is $11.27 and its 200-day moving average price is $11.03. Exicure has a 52-week low of $1.44 and a 52-week high of $36.00. The stock has a market capitalization of $53.32 million, a price-to-earnings ratio of -4.08 and a beta of 3.74.

Exicure (NASDAQ:XCUR) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Exicure

An institutional investor recently raised its position in Exicure stock. Carlyle Group Inc. raised its stake in shares of Exicure, Inc. (NASDAQ:XCUR) by 400.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 281,636 shares of the company’s stock after purchasing an additional 225,308 shares during the quarter. Exicure makes up about 0.9% of Carlyle Group Inc.’s holdings, making the stock its 11th biggest holding. Carlyle Group Inc. owned about 10.79% of Exicure worth $3,850,000 as of its most recent filing with the Securities and Exchange Commission. 42.82% of the stock is currently owned by hedge funds and other institutional investors.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.